Table III.
Company (Sponsor) | siRNA product | Disease | Administration | Phase | First received and last updated | Status |
---|---|---|---|---|---|---|
Opko Health, Inc. | Cand5 | AMD | Intravitreal injection | Phase II | Nov 30, 2005 | Completed |
Aug 4, 2008 | ||||||
Opko Health, Inc. | Cand5 (bevasiranib) | DR | Intravitreal injection | Phase II | Mar 23, 2006 | Completed |
July 24, 2008 | ||||||
Allergan | Sirna-027 | AMD | Intravitreal injection | Phase I | Aug 10, 2006 | Completed |
CNV | Phase II | Aug 14, 2008 | ||||
Allergan | Sirna-027 | AMD | Intravitreal injection | Phase II | Oct 31, 2006 | Terminated |
CNV | Aug 7, 2009 | |||||
Opko Health, Inc. | Compare bevasiranib and Lucentis® | AMD | Intravitreal injection | Phase III | Nov 13, 2007 | Withdrawn prior to enrollment |
Jun 16, 2011 | ||||||
Quark Pharmaceuticals | QPI-1007 | Chronic Optic Nerve Atrophy | Intravitreal injection | Phase I | Feb 4, 2010 | Active, not recruiting participants |
Apr 24, 2012 | ||||||
Sylentis, SA | SYL040012 | Glaucoma | Topical administration | Phase I | Oct 21, 2010 | Completed |
Ocular hypertension | Phase II | Sep26, 2012 | ||||
Sylentis, SA | SYL1001 | Dry eye | Topical administration | Phase I | Sep 14, 2011 | Completed |
Ocular pain | Jul 16, 2012 |
AMD Age-related macular degeneration
DR Diabetic retinopathy
CNV Choroidal ocular neovascularization